Advanced in Dementia

Dr. Mark Brody

Neurology

Health At Home

800 NW 17th Ave,

Delray Beach, FL

Advanced in Dementia

Health At Home

800 NW 17th Ave,

Delray Beach, FL

Overview

Mark Brody is a Neurologist in Delray Beach, Florida. Dr. Brody is rated as an Advanced provider by MediFind in the treatment of Dementia. His top areas of expertise are Alzheimer's Disease, Dementia, Memory Loss, and Cerebellar Degeneration.

His clinical research consists of co-authoring 6 peer reviewed articles and participating in 31 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 6 articles and participated in 28 clinical trials in the study of Dementia.

Specialties

Neurology

Licenses

Psychiatry & Neurology in FL

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance

Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield

Humana

HMO
INDEMNITY
POS
PPO

Managed Medicaid

OTHER MANAGED MEDICAID

Medicaid

OTHER MEDICAID
STATE MEDICAID

UnitedHealthcare

Walgreens

MEDICARE DISCOUNT CARD
MEDICARE PDP
OTHER MEDICARE

View 1 Less Insurance Carrier -

Locations

Health at Home
800 NW 17th Ave, Delray Beach, FL 33445

Call: 561-374-8461

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

29 Clinical Trials

A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease

Enrollment Status: Active_not_recruiting

Publish Date: January 21, 2026

Intervention Type: Drug

Study Drug: Donanemab

Study Phase: Phase 3

A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease

Enrollment Status: Completed

Publish Date: October 29, 2025

Intervention Type: Drug

Study Drug: AL002

Study Phase: Phase 2

Long-Term Nicotine Treatment of Mild Cognitive Impairment

Enrollment Status: Completed

Publish Date: October 01, 2025

Intervention Type: Drug

Study Drug: Nicotine Transdermal Patch

Study Phase: Phase 2

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 76-week Study Evaluating the Safety and Efficacy of Two Doses of Simufilam in Subjects With Mild-to-Moderate Alzheimer's Disease

Enrollment Status: Terminated

Publish Date: September 22, 2025

Intervention Type: Drug

Study Drug: Simufilam

Study Phase: Phase 3

Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease

Enrollment Status: Active_not_recruiting

Publish Date: August 29, 2025

Intervention Type: Drug

Study Drug: Donanemab

Study Phase: Phase 3

Assessment of Safety, Tolerability, and Efficacy of LY3372689 in Early Symptomatic Alzheimer's Disease

Enrollment Status: Completed

Publish Date: July 28, 2025

Intervention Type: Drug

Study Drug: LY3372689

Study Phase: Phase 2

A 12-Month, Open-Label Safety Study of Simufilam Followed by a 6-Month Randomized Withdrawal and 6 Additional Months Open-Label in Mild-to-moderate Alzheimer's Disease Patients

Enrollment Status: Completed

Publish Date: April 22, 2025

Intervention Type: Drug

Study Drug: Simufilam

Study Phase: Phase 2

A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects With Mild to Moderate Alzheimer's Disease

Enrollment Status: Completed

Publish Date: April 04, 2025

Intervention Type: Drug

Study Drug: ATH-1017

Study Phase: Phase 2/Phase 3

A Randomized , Double Blind, Placebo Controlled, 3-Arm Parallel Design Study to Evaluate the Effects of BPN14770 in Patients With Early Stage Alzheimer's Disease

Enrollment Status: Completed

Publish Date: February 18, 2025

Intervention Type: Drug

Study Drug: BPN14770

Study Phase: Phase 2

A Single- and Multiple-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Intravenous Doses of LY3002813 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease

Enrollment Status: Completed

Publish Date: October 08, 2024

Intervention Type: Biological, Drug

Study Phase: Phase 1

Trial Ready Cohort for the Prevention of Alzheimer's Dementia (TRC-PAD)

Enrollment Status: Completed

Publish Date: June 27, 2024

A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of AGB101on Slowing Progression of Mild Cognitive Impairment Due to Alzheimer's Disease

Enrollment Status: Completed

Publish Date: May 17, 2024

Intervention Type: Drug

Study Drug: AGB101

Study Phase: Phase 2/Phase 3

Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)

Enrollment Status: Completed

Publish Date: December 28, 2023

Intervention Type: Drug

Study Drug: Solanezumab

Study Phase: Phase 3

A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride

Enrollment Status: Completed

Publish Date: June 09, 2023

Intervention Type: Drug

Study Phase: Phase 2

GAIN Trial: A Randomized, Double-Blind, Placebo-Controlled Study of COR388 in Subjects With Alzheimer's Disease

Enrollment Status: Completed

Publish Date: February 23, 2023

Intervention Type: Drug

Study Drug: COR388

Study Phase: Phase 2/Phase 3

A Phase 2A Study to Evaluate Safety, Tolerability and Pharmacological Effects of PU AD in Subjects With Mild Alzheimer's Disease (AD) Dementia

Enrollment Status: Terminated

Publish Date: November 17, 2022

Intervention Type: Radiation, Behavioral, Diagnostic test, Drug

Study Drug: Dihydrochloride Salt

Study Phase: Phase 2

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of BIIB092 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease

Enrollment Status: Terminated

Publish Date: November 08, 2022

Intervention Type: Drug

Study Drug: BIIB092

Study Phase: Phase 2

Effects of Intravenous Delivery of Lomecel-B (Formerly Allogenic Longeveron Human Mesenchymal Stem Cells (LMSCs)) on VaccinE-Specific Antibody Responses in Subjects With Aging Frailty

Enrollment Status: Completed

Publish Date: November 04, 2022

Intervention Type: Biological

Study Phase: Phase 1/Phase 2

Assessment of Safety, Tolerability and Efficacy of LY3002813 in Early Symptomatic Alzheimer's Disease

Enrollment Status: Completed

Publish Date: October 13, 2022

Intervention Type: Drug

Study Drug: LY3002813

Study Phase: Phase 2

Assessment of Safety, Tolerability, and Efficacy of LY3303560 in Early Symptomatic Alzheimer's Disease

Enrollment Status: Completed

Publish Date: August 30, 2022

Intervention Type: Drug

Study Drug: LY3303560

Study Phase: Phase 2

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease

Enrollment Status: Terminated

Publish Date: September 02, 2021

Intervention Type: Drug

Study Phase: Phase 3

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment

Enrollment Status: Completed

Publish Date: October 01, 2020

Intervention Type: Other, Drug

Study Phase: Phase 2

A Multicenter Screening Study With Flortaucipir F 18 in Patients With Early Symptomatic AD

Enrollment Status: Completed

Publish Date: August 24, 2020

Intervention Type: Drug, Procedure

Study Phase: Phase 2

A Pilot, Phase 2a, Multi-Center, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Safety and Tolerability, Efficacy, and Pharmacokinetics of AD-35 in Subjects With Mild to Moderate Alzheimer's Disease

Enrollment Status: Unknown

Publish Date: March 25, 2020

Intervention Type: Drug

Study Drug: AD-35

Study Phase: Phase 2

A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia

Enrollment Status: Terminated

Publish Date: December 03, 2019

Intervention Type: Drug

Study Phase: Phase 3

A Randomized, Double-Blind, Delayed-Start Study of LY3314814 (AZD3293) in Early Alzheimer's Disease Dementia (Extension of Study AZES, The AMARANTH Study)

Enrollment Status: Terminated

Publish Date: December 03, 2019

Intervention Type: Drug

Study Phase: Phase 3

A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)

Enrollment Status: Terminated

Publish Date: December 03, 2019

Intervention Type: Drug

Study Phase: Phase 2/Phase 3

A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease

Enrollment Status: Terminated

Publish Date: October 10, 2019

Intervention Type: Drug

Study Phase: Phase 3

A Single-Dose and Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3372993 in Healthy Subjects and Patients With Alzheimer's Disease

Enrollment Status: Completed

Publish Date: June 05, 2019

Intervention Type: Drug

Study Phase: Phase 1

View 28 Less Clinical Trials

6 Total Publications

Allogeneic mesenchymal stem cell therapy with laromestrocel in mild Alzheimer's disease: a randomized controlled phase 2a trial.

Journal: Nature medicine

Published: April 12, 2024

View All 6 Publications

Similar Doctors

Elite in Dementia

Dr. Ranjan Duara

Neurology

Elite in Dementia

Dr. Ranjan Duara

Neurology

Mount Sinai Medical Center

4300 Alton Rd,

Miami Beach, FL

(44.6 miles away)

305-674-2543

Languages Spoken:

English

See accepted insurances

Offers Telehealth

Ranjan Duara is a Neurologist in Miami Beach, Florida. Dr. Duara is rated as a Distinguished provider by MediFind in the treatment of Dementia. His top areas of expertise are Memory Loss, Alzheimer's Disease, Dementia, and Developmental Dysphasia Familial.

Distinguished in Dementia

Dr. Carl Sadowsky

Neurology

Distinguished in Dementia

Dr. Carl Sadowsky

Neurology

Office

4631 N Congress Ave Ste 200,

West Palm Beach, FL

(20.7 miles away)

561-296-3846

Languages Spoken:

English

See accepted insurances

Carl Sadowsky is a Neurologist in West Palm Beach, Florida. Dr. Sadowsky is rated as an Advanced provider by MediFind in the treatment of Dementia. His top areas of expertise are Alzheimer's Disease, Dementia, Memory Loss, and Cerebellar Degeneration.

Distinguished in Dementia

Dr. Clinton Wright

Neurology

Distinguished in Dementia

Dr. Clinton Wright

Neurology

Epilepsy Foundation Of Florida

1150 NW 14th St Ste 609,

Miami, FL

(46.7 miles away)

305-243-6733

Languages Spoken:

English

Clinton Wright is a Neurologist in Miami, Florida. Dr. Wright is rated as a Distinguished provider by MediFind in the treatment of Dementia. His top areas of expertise are Noma, Stroke, CACH Syndrome, Dementia, and Thrombectomy.

VIEW MORE DEMENTIA DOCTORS

Frequently Asked Questions about Dr. Mark Brody

How do I make an appointment with Dr. Mark Brody?

You can book an appointment with Dr. Mark Brody by calling their office at 561-374-8461. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Mark Brody a top-rated expert for Alzheimer's Disease?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Mark Brody is classified as an Distinguished expert for Alzheimer's Disease, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Mark Brody specialize in?

While Dr. Mark Brody is a Neurology, they have specific expertise in Alzheimer's Disease, Dementia, and Memory Loss. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Neurology.

Does Dr. Mark Brody participate in research or clinical trials?

Yes. Dr. Mark Brody has published 6 articles and abstracts on conditions like Alzheimer's Disease. You can view a list of Dr. Mark Brody's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Mark Brody accept my insurance?

Dr. Mark Brody accepts most major insurance plans, including Blue Cross Blue Shield and Humana. We recommend calling the office directly at 561-374-8461 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Brody's expertise for a condition

ConditionClose